Citation Impact
Citing Papers
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice
2011 Nobel
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Cancer statistics, 2020
2020 Standout
Cancer Statistics, 2021
2021 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Post-remission therapy for acute myeloid leukemia
2014
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
The p38 MAPK stress pathway as a tumor suppressor or more?
2008
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
Signal integration by JNK and p38 MAPK pathways in cancer development
2009 Standout
New treatment for acute myelogenous leukemia
2014
Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma - Endpoints of a Spectrum of One Disease?
2013
Rituximab
2003
The emerging role of lncRNAs in cancer
2015 Standout
The Decapping Scavenger Enzyme DCS-1 Controls MicroRNA Levels in Caenorhabditis elegans
2013 StandoutNobel
Shiga Toxin Receptor Glycolipid Binding: Pathology and Utility
2003
MicroRNA sponges: Progress and possibilities
2010
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
The changing landscape of atherosclerosis
2021 StandoutNature
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
2011 Standout
Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome
2005 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
The multilayered complexity of ceRNA crosstalk and competition
2014 StandoutNature
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Metazoan MicroRNAs
2018 Standout
A trio of microRNAs that control Toll-like receptor signalling
2011
Biodistribution and function of extracellular miRNA-155 in mice
2015 StandoutNobel
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
Angiogenesis in life, disease and medicine
2005 StandoutNature
Endothelial cell effects of cytotoxics: balance between desired and unwanted effects
2004
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
TET enzymes, TDG and the dynamics of DNA demethylation
2013 StandoutNature
Non-coding RNAs in human disease
2011 Standout
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
High‐level expression, activation, and subcellular localization of p38‐MAP kinase in thyroid neoplasms
2006
p38α MAP Kinase as a Sensor of Reactive Oxygen Species in Tumorigenesis
2007
Chemistry in living systems
2005 StandoutNobel
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
Macrophage plasticity and polarization: in vivo veritas
2012 Standout
Microtubules as a target for anticancer drugs
2004 Standout
Tumor-associated macrophages: functional diversity, clinical significance, and open questions
2013
Leukaemogenesis: more than mutant genes
2009
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson
2013
DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis
2020 StandoutNatureNobel
Therapy with azanucleosides for myelodysplastic syndromes
2010
p38 MAP Kinase's Emerging Role as a Tumor Suppressor
2004
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Angiogenesis as a therapeutic target
2005 StandoutNature
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Tumor Angiogenesis
2008 Standout
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
2003
Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology
2015
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
2017 StandoutNature
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
2011
The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
2017
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
2014
Recent developments in myelodysplastic syndromes
2014
Acute Myeloid Leukemia
2015 Standout
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome
2011
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
2016
Review: Practical considerations in ovarian cancer chemotherapy
2010
Innate Immune Recognition of Cancer
2015
MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice
2013 Nobel
Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group
2005
Toward the potential cure of leukemias in the next decade
2018
Monoclonal Antibody Therapy for Cancer
2003
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
2014
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Ribosomopathies: human disorders of ribosome dysfunction
2010
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
2007
CAR T cell immunotherapy for human cancer
2018 StandoutScience
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
microRNA Regulation of Inflammatory Responses
2012 Nobel
Lenalidomide efficacy in activated B ‐cell‐like subtype diffuse large B ‐cell lymphoma is dependent upon IRF 4 and cereblon expression
2012
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
2005
Works of Rena Buckstein being referenced
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
2012
Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value
2003
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma
2011
Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype
2009
Treatment options for patients with acute myeloid leukemia with a matched sibling donor
2003
Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: A retrospective study of 322 bone marrows
2009
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non‐Hodgkin lymphoma of distinct histological origin
2011
Phase II Testing of Sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185
2007
Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma
2002
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
2011
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma
2002
Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
1999
A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117
2014
Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide
2004
Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
1999
Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117
2015
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
2009
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
2012
Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy
2003
High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma
2006
Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide
2004